BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 29366442)

  • 1. DNA binding partners of YAP/TAZ.
    Kim MK; Jang JW; Bae SC
    BMB Rep; 2018 Mar; 51(3):126-133. PubMed ID: 29366442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
    Meng Z; Moroishi T; Mottier-Pavie V; Plouffe SW; Hansen CG; Hong AW; Park HW; Mo JS; Lu W; Lu S; Flores F; Yu FX; Halder G; Guan KL
    Nat Commun; 2015 Oct; 6():8357. PubMed ID: 26437443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
    Jang JW; Kim MK; Bae SC
    Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hippo-YAP/TAZ signaling in angiogenesis.
    Park JA; Kwon YG
    BMB Rep; 2018 Mar; 51(3):157-162. PubMed ID: 29366443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative Real-Time PCR to Measure YAP/TAZ Activity in Human Cells.
    Cao X; Zhao B
    Methods Mol Biol; 2019; 1893():137-152. PubMed ID: 30565132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.
    Rashidian J; Le Scolan E; Ji X; Zhu Q; Mulvihill MM; Nomura D; Luo K
    Sci Signal; 2015 Feb; 8(363):ra14. PubMed ID: 25670202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
    Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
    J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of Hippo-YAP/TAZ signaling pathway in mechanotransduction.].
    Ishihara E; Nishina H
    Clin Calcium; 2016; 26(12):1751-1756. PubMed ID: 27885187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of RUNX in Hippo Pathway Signaling.
    Passaniti A; Brusgard JL; Qiao Y; Sudol M; Finch-Edmondson M
    Adv Exp Med Biol; 2017; 962():435-448. PubMed ID: 28299672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Hippo Pathway Prevents YAP/TAZ-Driven Hypertranscription and Controls Neural Progenitor Number.
    Lavado A; Park JY; Paré J; Finkelstein D; Pan H; Xu B; Fan Y; Kumar RP; Neale G; Kwak YD; McKinnon PJ; Johnson RL; Cao X
    Dev Cell; 2018 Dec; 47(5):576-591.e8. PubMed ID: 30523785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase.
    Serrano I; McDonald PC; Lock F; Muller WJ; Dedhar S
    Nat Commun; 2013; 4():2976. PubMed ID: 24356468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
    Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
    J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mammalian Hippo pathway: regulation and function of YAP1 and TAZ.
    Kodaka M; Hata Y
    Cell Mol Life Sci; 2015 Jan; 72(2):285-306. PubMed ID: 25266986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ.
    Yi J; Lu L; Yanger K; Wang W; Sohn BH; Stanger BZ; Zhang M; Martin JF; Ajani JA; Chen J; Lee JS; Song S; Johnson RL
    Hepatology; 2016 Nov; 64(5):1757-1772. PubMed ID: 27531557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YAP and TAZ Take Center Stage in Cancer.
    Zhang K; Qi HX; Hu ZM; Chang YN; Shi ZM; Han XH; Han YW; Zhang RX; Zhang Z; Chen T; Hong W
    Biochemistry; 2015 Nov; 54(43):6555-66. PubMed ID: 26465056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.
    Santucci M; Vignudelli T; Ferrari S; Mor M; Scalvini L; Bolognesi ML; Uliassi E; Costi MP
    J Med Chem; 2015 Jun; 58(12):4857-73. PubMed ID: 25719868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
    Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
    Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
    Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
    Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
    Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
    J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the Hippo Pathway Transcription Factor TEAD.
    Lin KC; Park HW; Guan KL
    Trends Biochem Sci; 2017 Nov; 42(11):862-872. PubMed ID: 28964625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.